Exercise of RSUs and options LONDON, UK / ACCESS Newswire / November 4, 2025 / Orosur Mining Inc. ("Orosur" or the "Company") (TSXV:OMI)(AIM:OMI) announces the following: The Company has issued 4,358,332 Common Shares ("Shares") representing 1.13% of the Company's current issued share capital, following the exercise of 3,123,332 RSUs and 1,280,000 options by directors and consultants of the Company. All of the directors will be retaining their Shares and not selling after exercise. ...

Financial Data and Key Metrics Changes - Revenue for Q3 2025 was $697 million, up from just under $687 million in Q3 2024, with a year-to-date revenue of nearly $2.1 billion, reflecting a 3.4% increase [14][15][18] - Adjusted EBITDA for Q3 2025 was $92 million, down from $108 million in Q3 2024, impacted by a one-time revenue benefit from the previous year [16][18] - Adjusted net income per share was $0.25 for Q3 2025, compared to $0.36 in Q3 2024, while year-to-date adjusted net income per share increased to $0.80 from $0.64 [18] Business Line Data and Key Metrics Changes - Year-over-year growth was noted in sleep therapy, ostomy, and urology categories, while diabetes showed flat performance compared to Q3 2024 but improved from Q2 2025 [15][16] - The company is focusing on improving therapy adherence and expanding customer capture across its ecosystem [15] Market Data and Key Metrics Changes - The company is positioned to benefit from the growing prevalence of chronic conditions such as diabetes and sleep apnea, with over 37 million diagnosed with diabetes and an estimated 85 million adults affected by obstructive sleep apnea in the U.S. [8][9] Company Strategy and Development Direction - The company announced a definitive agreement to sell its Products and Healthcare Services segment to Platinum Equity, allowing it to focus on its Patient Direct business and home-based care [5][6] - Future investments will prioritize technology and automation to enhance patient experience and operational efficiency [9][11] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the home-based care business and the potential for growth following the divestiture, emphasizing a unified strategic focus [11][22] - The company anticipates a strong 2026, despite a significant customer loss, and plans to manage operational costs and improve cash flow [27][30] Other Important Information - The company expects to incur approximately $40 million in annualized stranded costs from the divestiture [18] - As of September 30, net debt was $2.1 billion, with expectations for slight reduction by year-end [19][20] Q&A Session Summary Question: Durability of trends going into 2026 and selling into the Optum channel - Management indicated that the Optum channel is new and expected to create more opportunities, with guidance for 2026 to be provided closer to year-end [26][27] Question: Outlook for 2026 and free cash flow trends - Management expects decent top-line growth and margin improvement in 2026, with free cash flow trends anticipated to remain stable despite some one-off costs [30][32] Question: Details on preferred provider agreements and filling the Kaiser contract loss - Management noted that it would take less revenue growth to cover the loss of the Kaiser contract due to its low margin nature, and emphasized the importance of preferred provider agreements [37][39] Question: Clarification on cash flow and balance sheet issues - Management explained that cash flow challenges were related to startup costs of a new kitting facility and over-acquired inventory, which are expected to normalize over time [40][42]

Financial Data and Key Metrics Changes - Revenue for Q3 2025 was $697 million, up from nearly $687 million in Q3 2024, with a notable one-time revenue benefit of $6 million in the previous year impacting growth rates [15][19] - Adjusted EBITDA for Q3 2025 was $92 million, down from $108 million in Q3 2024, affected by the same one-time benefit and increased product costs [17][19] - Adjusted net income per share was $0.25 compared to $0.36 in 2024, while year-to-date adjusted net income per share was $0.80 versus $0.64 in the same period last year [19] Business Line Data and Key Metrics Changes - Key categories showing year-over-year growth included sleep therapy, ostomy, and urology, while diabetes revenue remained nearly flat compared to 2024 [15][16] - The company is focusing on improving therapy adherence and expanding customer capture across its ecosystem to drive stronger diabetes growth [16] Market Data and Key Metrics Changes - The U.S. market has over 37 million diagnosed diabetes patients and approximately 85 million adults with some degree of obstructive sleep apnea (OSA), presenting significant growth opportunities for the company [8][9] - The company is actively collaborating with industry partners to maintain a strong dialogue regarding competitive bidding programs in home-based healthcare [10] Company Strategy and Development Direction - The company announced a definitive agreement to sell its Products and Healthcare Services segment, allowing it to focus solely on the home-based care business [5][6] - Future investments will prioritize technology and automation to enhance customer experience and operational efficiency [7][8] - The company aims to improve cash flow and financial flexibility by prioritizing debt repayment following the divestiture [6][11] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the future as a pure-play home-based care company, anticipating strong organic growth and improved cash flow despite the loss of a large customer contract [26][30] - The company expects to maintain compliance with covenants and remain financially stable post-divestiture [33] Other Important Information - Year-to-date stranded costs were $25 million, down from $39 million in the same period in 2024, with expectations of annualized stranded costs around $40 million [19] - The company reported $28 million of free cash flow in Q3 and $78 million for the first nine months of the year [22] Q&A Session Summary Question: How should the company think about the durability of trends going into 2026? - Management indicated that while they cannot provide specific 2026 data yet, they expect strong trends to continue, barring a significant customer loss [24][26] Question: What is the outlook for free cash flow in 2025 and beyond? - Management expects Q4 to resemble Q3 in terms of free cash flow, with improvements anticipated in 2026 due to the loss of a less profitable contract [30][31] Question: Are there any risks to covenants post-divestiture? - Management confirmed that they are in compliance with covenants and expect to remain so [33] Question: How do preferred vendor agreements work, and how will the company fill the gap from the lost contract? - Management stated that it will take fewer contracts to cover the lost contract's EBITDA and cash flow, emphasizing the favorable margins of new agreements [36][41] Question: Can you elaborate on the cash flow issues related to the new kitting facility? - Management explained that startup costs and over-acquired inventory for the new facility are impacting cash flow, but these issues are expected to resolve in the coming months [42][44]

Financial Performance - Net loss from continuing operations per common share was ($0.07) for Q3 2025, compared to $0.02 for Q3 2024, impacted by an increase in intangible amortization of $21 million and costs of net revenue of $20 million [135]. - Net revenue for the three months ended September 30, 2025, was $697.3 million, an increase of $10.4 million or 1.5% compared to $686.8 million in Q3 2024 [143]. - For the nine months ended September 30, 2025, net revenue was $2.05 billion, up $68 million or 3.4% from $1.99 billion in the same period of 2024 [143]. - The increase in net revenue for Q3 2025 was driven by sales growth in sleep therapy (4.9%), ostomy (5.4%), and urology (4.4%) product categories [144]. - Cost of net revenue for Q3 2025 was $375.1 million, an increase of $20 million or 5.6% from $355.1 million in Q3 2024 [145]. - Selling, general and administrative expenses for Q3 2025 decreased by $6.5 million or 2.4% to $265.8 million, representing 38.13% of net revenue [146]. - Adjusted EBITDA for Q3 2025 was $92,174,000, down 14.4% from $107,672,000 in Q3 2024 [157]. - For the nine months ended September 30, 2025, Adjusted EBITDA increased to $284,827,000, up 6.7% from $267,970,000 in the same period of 2024 [159]. Transaction and Acquisition Activities - The company incurred a transaction breakage fee of $80 million related to the terminated acquisition of Rotech [147]. - The company announced the sale of its Products & Healthcare Services segment for $375 million, expected to close in Q1 2026 [138]. - Acquisition-related charges for the nine months ended September 30, 2025, were $66.6 million, up 55.2% from $42.9 million in the same period of 2024 [148]. - The proposed acquisition of Rotech was terminated on June 3, 2025, leading to the redemption of the New Notes at 100% of the aggregate principal amount [182]. - The company completed a private offering of $1.0 billion aggregate principal amount of Senior Secured Notes due 2030 to finance a proposed acquisition of Rotech [181]. Tax and Compliance - Income tax provision for Q3 2025 was $1,972,000, a significant increase of $2,275,000 or 750.8% compared to a benefit of $303,000 in Q3 2024 [154]. - The effective tax rate for the nine months ended September 30, 2025, was 0.8%, a significant decrease from 32.2% in the same period of 2024 [154]. - The company was in compliance with its debt covenants as of September 30, 2025 [180]. Cash Flow and Liquidity - Cash and cash equivalents increased by $5,265,000 or 19.1% to $32,837,000 as of September 30, 2025, compared to $27,572,000 at the end of 2024 [169]. - Accounts receivable decreased by $15,539,000 or 7.1% to $202,731,000 as of September 30, 2025, from $218,270,000 at the end of 2024 [169]. - Cash used for operating activities in the first nine months of 2025 was $(169,976,000), reflecting a net loss impacted by an $80 million termination fee related to the Rotech acquisition [170]. - Cash provided by financing activities in the first nine months of 2025 included net borrowings of $271,000,000 under the Revolving Credit Facility [174]. - The company has a revolving borrowing capacity of $450 million and $837 million in outstanding term loans as of September 30, 2025 [177]. - As of September 30, 2025, the company had $271 million in outstanding borrowings on its Revolving Credit Agreement, with $150 million available for borrowing after accounting for letters of credit [179]. - A share repurchase program of up to $100 million was authorized, with $6.6 million spent to repurchase 826 thousand shares at an average price of $8.04 during the nine months ended September 30, 2025 [184]. - Cash and cash equivalents held by foreign subsidiaries subject to repatriation totaled $13 million and $22 million at September 30, 2025, and December 31, 2024, respectively [186]. - The company believes it has sufficient cash generated from operating activities and available financing sources to meet its working capital needs [185]. Risks and Challenges - A commercial payor's contract termination is expected to impact $242 million or 12% of net revenue, primarily affecting capitation revenue [142]. - The company faces various risks, including competitive pressures, dependence on key customers and suppliers, and uncertainties related to international operations and regulatory changes [190]. - The company expects to amend the Receivables Sale Program to expand sales of Patient Direct receivables following the sale of its P&HS segment [185].

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Financial Performance Outlook - The company projects full year 2025 revenue between $2.76 billion and $2.82 billion[6] - Adjusted EBITDA is expected to be in the range of $376 million to $382 million[6] - The company anticipates adjusted net income between $81 million and $85 million[6] - Adjusted EPS is projected to be between $1.02 and $1.07[6] Key Financial Metrics - Interest expense is estimated to be between $104 million and $107 million[6] - Gross capital expenditures are expected to be between $205 million and $215 million[6] - Net capital expenditures are projected to be between $135 million and $145 million[6] - The adjusted effective tax rate is expected to be between 29.5% and 30.5%[6] Important Considerations - The company's outlook includes forward-looking statements subject to risks and uncertainties, and actual results may differ materially[2] - The presentation includes non-GAAP financial measures used by management to evaluate performance, but these should not be considered substitutes for GAAP measures[3, 5]

Financial Performance - Third quarter 2025 revenue was $697.3 million, a 1.5% increase from $686.8 million in Q3 2024[4] - Adjusted net income from continuing operations for Q3 2025 was $19.9 million, down 29.4% from $28.2 million in Q3 2024[4] - Adjusted EBITDA for Q3 2025 was $92.2 million, a decrease of 14.4% compared to $107.7 million in Q3 2024[4] - The company reported a net loss of $150.3 million in Q3 2025, compared to a net loss of $12.8 million in Q3 2024[11] - For the first nine months of 2025, net revenue was $2.05 billion, up 3.4% from $1.99 billion in the same period of 2024[12] - The company reaffirmed its 2025 revenue guidance of between $2.76 billion and $2.82 billion[5] - Adjusted EPS for 2025 is expected to range between $1.02 and $1.07[5] - Total net loss for the nine months ended September 30, 2025, was $1,044,316 thousand, a substantial increase from a net loss of $66,570 thousand in the same period of 2024[16] - Basic loss per common share for the three months ended September 30, 2025, was $(1.94), compared to $(0.17) for the same period in 2024[17] - Adjusted net income for Q3 2025 was $19,863,000, compared to $28,235,000 in Q3 2024[24] - The adjusted earnings per share (EPS) for Q3 2025 was $0.25, down from $0.36 in Q3 2024[24] Cash Flow and Assets - The total assets as of September 30, 2025, were $4.04 billion, down from $4.66 billion at the end of 2024[13] - Current liabilities increased to $2.47 billion as of September 30, 2025, compared to $1.85 billion at the end of 2024[13] - The company experienced a net cash used in operating activities of $172,520 thousand for the three months ended September 30, 2025, compared to cash provided by operating activities of $27,307 thousand in 2024[15] - Cash, cash equivalents, and restricted cash at the end of the period on September 30, 2025, totaled $46,166 thousand, down from $75,090 thousand at the end of the same period in 2024[16] - Cash provided by financing activities for the nine months ended September 30, 2025, was $305,574 thousand, compared to cash used of $224,507 thousand in 2024[16] Operational Highlights - The company is focusing on home-based care and has signed a nationwide preferred provider partnership agreement[2] - Operating income for Q3 2025 was reported at $26,470,000, a decrease from $31,079,000 in Q3 2024, while adjusted operating income was $58,124,000 compared to $69,433,000 in the same period[22] - The company incurred acquisition-related charges and intangible amortization of $29,229,000 in Q3 2025, up from $14,855,000 in Q3 2024[24] - Exit and realignment charges for Q3 2025 were $660,000, significantly lower than $13,515,000 in Q3 2024[24] - The company recorded a goodwill impairment charge of $106,389 thousand and a loss on classification to held for sale of $771,640 thousand during the nine months ended September 30, 2025[16] Future Outlook and Strategic Initiatives - Future outlook projects a revenue growth of 8-10% for the next fiscal year, driven by new product launches[39] - The company is investing $50 million in R&D for new technologies aimed at enhancing supply chain efficiency[39] - Market expansion efforts include entering three new international markets, expected to contribute an additional $100 million in revenue[39] - Owens & Minor completed the acquisition of a smaller competitor, which is anticipated to increase market share by 5%[39] - The company plans to launch two new product lines in Q2 2024, targeting a market size of $500 million[39] - Cost-saving initiatives are projected to reduce operational expenses by 3% over the next year[39] - The company has set a goal to achieve carbon neutrality by 2030, aligning with sustainability strategies[39]

Core Insights - Orosur Mining Inc. has released its audited financial results for the first quarter ending August 31, 2025, indicating a focus on transparency and accountability in financial reporting [1] Financial Performance - The financial results are presented in thousands of US dollars, emphasizing the company's commitment to clear financial communication [1]

Core Insights - U.S. stocks experienced a mostly positive session, with the Dow Jones index increasing by over 150 points on Friday [1] Company Highlights - Revolution Medicines Inc (NASDAQ:RVMD) saw a significant share price increase of 11.2%, reaching $55.25, after the FDA granted a non-transferrable voucher for its drug daraxonrasib under the National Priority Voucher pilot program [1] - Disc Medicine Inc (NASDAQ:IRON) shares surged by 25.7% to $93.50 following the receipt of a Commissioner's National Priority Voucher from the FDA for bitopertin [4] - Liberty Energy Inc (NYSE:LBRT) reported a 23.4% increase in share price to $14.73 after announcing third-quarter results [4] - Solana Co (NASDAQ:HSDT) shares rose by 19.5% to $12.08 [4] - Sealsq Corp (NASDAQ:LAES) experienced a 14.4% increase, reaching $7.28 [4] - Rekor Systems Inc (NASDAQ:REKR) shares gained 13.3% to $2.94 [4] - Praxis Precision Medicines Inc (NASDAQ:PRAX) saw a 12.5% increase to $183.00 after announcing a $525 million public offering [4] - Sify Technologies Ltd (NYSE:SIFY) shares rose by 11.8% to $13.15 [4] - Kenvue Inc (NYSE:KVUE) increased by 8.4% to $15.30 [4] - Propetro Holding Corp (NYSE:PUMP) surged by 7.6% to $5.52 [4] - Owens & Minor Inc (NYSE:OMI) shares gained 6.7% to $4.90 [4] - American Express Co (NYSE:AXP) reported a 6% increase in share price to $342.57, surpassing analyst estimates for revenue and adjusted earnings per share [4] - AppFolio Inc (NASDAQ:APPF) shares increased by 4.7% to $233.90, with an upgrade from Keybanc analyst Jason Celino from Sector Weight to Overweight and a new price target of $285 [4]

Core Viewpoint - Orosur Mining Inc has conducted an Investor Presentation on October 15, 2025, which is now available for viewing on the company's website [1] Company Information - Orosur Mining Inc operates in Colombia, Argentina, and Nigeria as a mineral explorer and developer [1] - The company can be contacted through various representatives, including Louis Castro (Executive Chairman) and Brad George (CEO) [1] Investor Communication - The presentation can be accessed via the company's investor relations page [1] - Additional information can be found on the company's website and social media platforms [1]